Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine

DOI 10.1038/74704

Cited by (1,006)

Items 601–700 of 1,006

MicroRNA-127 Inhibits Lung Inflammation by Targeting IgG Fcγ Receptor I
Ting Xie, Jiurong Liang, Ningshan Liu, Qingguo Wang, Yuhang Li, Paul W. Noble, Dianhua Jiang · 2012 · The Journal of Immunology
Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab
Guoxu Zheng, Zhangyan Guo, Weimiao Li, Wenjin Xi, Baile Zuo, Rui Zhang, Weihong Wen, Angang Yang, Lintao Jia · 2021 · Signal Transduction and Targeted Therapy
Engineering therapeutic monoclonal antibodies
Xiao‐Yun Liu, Laurentiu M. Pop, Ellen S. Vitetta · 2008 · Immunological Reviews
Unraveling the Biologic and Clinical Complexities of HER2
John W. Park, Richard M. Neve, János Szöllõsi, Christopher C. Benz · 2008 · Clinical Breast Cancer
Recombinant antibodies for cancer diagnosis and therapy
Christelle Souriau, Peter J. Hudson · 2003 · Expert Opinion on Biological Therapy
Humanized tumor mice—A new model to study and manipulate the immune response in advanced cancer therapy
Anja Kathrin Wege, Wolfgang Ernst, Judith Eckl, Bernhard Frankenberger, Arabel Vollmann‐Zwerenz, Daniela N. Männel, Olaf Ortmann, Alexander Kroemer, Gero Brockhoff · 2011 · International Journal of Cancer
Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers
Tsutomu Oshima, Shuji Sato, Junichi Kato, Yuki Ito, Takahiro Watanabe, Isamu Tsuji, Akira Hori, Tomofumi Kurokawa, Toshio Kokubo · 2013 · Molecular Cancer
Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell–mediated antibody-dependent cellular cytotoxicity
Dominika Rudnicka, Anna Oszmiana, Donna K. Finch, Ian Strickland, Darren J. Schofield, David C. Lowe, Matthew A. Sleeman, Daniel M. Davis · 2013 · Blood
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
Wilhem Leconet, Christel Larbouret, Thierry Chardès, Gaëlle Thomas, Madeline Neiveyans, Muriel Busson, Marta Jarlier, Nina Radosevic‐Robin, Martine Pugnière, Florence Bernex et al. · 2013 · Oncogene
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
Fubin Li, Jeffrey V. Ravetch · 2012 · Proceedings of the National Academy of Sciences
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Tanios Bekaii‐Saab, Julie M. Roda, Kristan D. Guenterberg, B Ramaswamy, Donn C. Young, Amy K. Ferketich, Tammy Lamb, Michael R. Grever, Charles L. Shapiro, William Edgar Carson · 2009 · Molecular Cancer Therapeutics
The Importance of Human FcγRI in Mediating Protection to Malaria
Richard Stephen McIntosh, Jianguo Shi, Richard M. Jennings, Jonathan C Chappel, Tania F. de Koning‐Ward, Tim Smith, Judith L. Green, Marjolein van Egmond, Jeanette H.W. Leusen, Maria Lazarou et al. · 2007 · PLoS Pathogens
FcγRs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics
Yuanyuan Xu, Alexander J. Szalai, Tong Zhou, Kurt R. Zinn, Tandra R. Chaudhuri, Xiaoli Li, William J. Koopman, Robert P. Kimberly · 2003 · The Journal of Immunology
Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
Lucie Baudino, Yasuro Shinohara, Falk Nimmerjahn, Jun‐ichi Furukawa, Munehiro Nakata, Eduardo Martínez-Soria, Franz Petry, Jeffery V. Ravetch, Shin‐Ichiro Nishimura, Shozo Izui · 2008 · The Journal of Immunology
Evolution of anti- CD20 monoclonal antibody therapeutics in oncology
Ezogelin Oflazoglu, Laurent Audoly · 2010 · mAbs
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Howard A. Burris, Jay Tibbitts, Scott N. Holden, Mark X. Sliwkowski, Gail D. Lewis Phillips · 2011 · Clinical Breast Cancer
Role of tumor-derived exosomes in cancer metastasis
Ian J.Y. Wee, Nicholas L. X. Syn, Gautam Sethi, Boon Cher Goh, Lingzhi Wang · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.
E. Keystone, G. Burmester, R. Furie, J. Loveless, P. Emery, J. Kremer, P. Tak, M. Broder, E. Yu, M. Cravets et al. · 2008 · Arthritis & Rheumatism
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells
Panagiotis Karagiannis, Josef Singer, James Hunt, Samuel Ken‐En Gan, Sarah Maria Rudman, Diana Mechtcheriakova, Regina Knittelfelder, Tracy R. Daniels‐Wells, Philip S. Hobson, Andrew J. Beavil et al. · 2008 · Cancer Immunology Immunotherapy
Computational Modeling of ERBB2 -Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
Daniel C. Kirouac, Jin Y. Du, Johanna Lahdenranta, Ryan P. Overland, Defne Yarar, Violette B. Paragas, Emily A. Pace, Charlotte Fenton McDonagh, Ulrik B. Nielsen, Matthew David Onsum · 2013 · Science Signaling
Human antibodies as next generation therapeutics
Marc A. van Dijk, Jan G. J. van de Winkel · 2001 · Current Opinion in Chemical Biology
The role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, Josée, Taylor, Ronald P. · 2020 · Antibodies
An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer
Carlo C. Maley, Konrad Koelble, Rachael Natrajan, Athena Aktipis, Yinyin Yuan · 2015 · Breast Cancer Research
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
Aleksander F. Sikorski, Monika Toporkiewicz, Justyna M. Meissner, Lucyna Matusewicz, Aleksander Czogalla · 2015 · International Journal of Nanomedicine
Immunotherapy in endometrial cancer: rationale, practice and perspectives
Wenyu Cao, Xinyue Ma, Jean Victoria Fischer, Chenggong Sun, Beihua Kong, Qing Hua Zhang · 2021 · Biomarker Research
Muc4/MUC4 Functions and Regulation in Cancer
Kermit L. Carraway, George Theodoropoulos, Goldi A. Kozloski, Coralie A. Carothers Carraway · 2009 · Future Oncology
Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies
Alicia Viloria‐Petit, Robert S. Kerbel · 2004 · International Journal of Radiation Oncology*Biology*Physics
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/ neu -Transgenic Mice
Matthew E. Wolpoe, Eric R. Lutz, Anne M. Ercolini, Satoshi Murata, Susan E. Ivie, Elizabeth S. Garrett, Leisha A. Emens, Elizabeth M. Jaffee, R. Todd Reilly · 2003 · The Journal of Immunology
Trastuzumab deruxtecan in breast cancer
Martín, Miguel, Pandiella, Atanasio, Vargas-Castrillón, Emilio, Díaz-Rodríguez, Elena, Iglesias-Hernangómez, Teresa, Martínez Cano, Concha, Fernández-Cuesta, Inés, Winkow, Elena, Perelló, Maria Francesca · 2024 · Critical Reviews in Oncology/Hematology
Rituximab: mechanisms and applications
Peter Johnson, Martin J. Glennie · 2001 · British Journal of Cancer
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
Julie A. McEarchern, Ezogelin Oflazoglu, Leigh V. Francisco, Charlotte Fenton McDonagh, Kristine A. Gordon, Ivan J. Stone, Kerry Klussman, Eileen Turcott, Nico van Rooijen, Paul M. Carter et al. · 2006 · Blood
Interleukin 21: combination strategies for cancer therapy
Kresten Skak, Michael Kragh, Diana Felice Hausman, Mark John Smyth, Pallavur V. Sivakumar · 2008 · Nature Reviews Drug Discovery
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Dylan Daniel, Becky Yang, David A. Lawrence, Klára Tótpál, Inessa Balter, Wyne P. Lee, Alvin Gogineni, Mary J. Cole, Sharon Fong Yee, Sarajane Ross et al. · 2007 · Blood
Targeting innate sensing in the tumor microenvironment to improve immunotherapy
Zhida Liu, Chuanhui Han, Yang‐Xin Fu · 2019 · Cellular and Molecular Immunology
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhuo Zhang, Meili Zhang, Carolyn K. Goldman, Jeffrey V. Ravetch, Thomas A. Waldmann · 2003 · PubMed
Immunotherapy of Non-Hodgkin's Lymphomas
Oliver W. Press, John Paul Leonard, Bertrand Coiffier, Ronald Levy, John M. Timmerman · 2001 · Hematology
The clinical pharmacology of therapeutic monoclonal antibodies
Lorin K. Roskos, Clay Davis, Gisela M. Schwab · 2004 · Drug Development Research
The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates
Jonathan Zalevsky, Irene Leung, Sher Karki, Seung Y. Chu, Eugene A. Zhukovsky, John R. Desjarlais, David F. Carmichael, Chris E. Lawrence · 2008 · Blood
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Jiajing Cai, Qi Qi, Xuemeng Qian, Jia Gang. Han, Xinfang Zhu, Qi Zhang, Rong Xia · 2019 · Journal of Cancer Research and Clinical Oncology
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Christina Haeyoung Yeon, Mark Daniel Pegram · 2005 · Investigational New Drugs
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett, Cammie R. Sutton, María Gabriela Kuba, Rebecca S. Cook, Carlos L. Arteaga · 2012 · Clinical Cancer Research
Regulation of efferocytosis as a novel cancer therapy
Zhou, Yunxiang, Yao, Yihan, Deng, Yongchuan, Shao, Anwen · 2020 · Cell Communication and Signaling
Tumor necrosis factor α release is a major biological event associated with rituximab treatment
Jacques Bienvenu, Roland Chvetzoff, Gilles Salles, Cécile Balter, Hervé Tilly, Raoul Herbrecht, Pierre Morel, Pierre Lederlin, Philippe Solal‐Céligny, Bruno Audhuy et al. · 2001 · The Hematology Journal
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
Stefanie Naundorf, Susanne Preithner, Petra Mayer, Sandra Lippold, Andreas Wolf, Frank Hanakam, Iduna Fichtner, Peter Kufer, Tobias Raum, Gert Riethmüller et al. · 2002 · International Journal of Cancer
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production
Jaime-Ramirez, Alena Cristina, Mundy-Bosse, Bethany L, Kondadasula, SriVidya, Jones, Natalie B, Roda, Julie M, Mani, Aruna, Parihar, Robin, Karpa, Volodymyr, Papenfuss, Tracey L, LaPerle, Krista M et al. · 2011 · The Journal of Immunology
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia
Issa F. Khouri, Roland L. Bassett, Nancy J Poindexter, Susan Mary O'Brien, Carlos Bueso-Ramos, Yvonne Hsu, Alessandra Ferrajoli, Michael J. Keating, Richard E. Champlin, Marcelo Fernández-Viña · 2011 · Cancer
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Christian Kellner, Anna Otte, Elisa Cappuzzello, Katja Klausz, Matthias Peipp · 2017 · Transfusion Medicine and Hemotherapy
Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
Falk Nimmerjahn, Gestur Vidarsson, Mark Steven Cragg · 2023 · Nature Immunology
Effective Cancer Therapy Through Immunomodulation
Thomas A. Waldmann · 2005 · Annual Review of Medicine
Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
John F. DiJoseph, Mary E.P. Goad, Maureen M. Dougher, Erwin R. Boghaert, Arthur Kunz, Philip R. Hamann, Nitin K. Damle · 2004 · Clinical Cancer Research
A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma
Khuda Dad Khan, Christos E. Emmanouilides, Don M. Benson, Deborah Hurst, Pablo Garcia, Glenn C. Michelson, Sandra Milan, Amy K. Ferketich, Lawrence D. Piro, John Paul Leonard et al. · 2006 · Clinical Cancer Research
AACR Cancer Progress Report 2014
Carlos L. Arteaga, Peter C. Adamson, Jeffrey A. Engelman, Margaret Foti, Richard B. Gaynor, Susan Galloway Hilsenbeck, Paul J. Limburg, Scott W. Lowe, Elaine R. Mardis, Scott Ramsey et al. · 2014 · Clinical Cancer Research
Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells
Gabrielle Romain, Vladimir Senyukov, Nicolas Rey-Villamizar, Amine Merouane, William Kelton, Ivan Liadi, Ankit Mahendra, Wissam Charab, George Georgiou, Badrinath Roysam et al. · 2014 · Blood
Targeting tumor-associated macrophages to combat pancreatic cancer
Ran Cui, Wen Yue, Edmund C. Lattime, Mark N. Stein, Qing Xu, Xiang‐Lin Tan · 2016 · Oncotarget
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Xun Gui, Mi Deng, Hao Song, Yuanzhi Chen, Jingjing Xie, Zunling Li, Licai He, Fangfang Huang, Yixiang Xu, Yasuaki Anami et al. · 2019 · Cancer Immunology Research
Functions of Antibodies
Donald N. Forthal · 2015 · ASM Press eBooks
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity
Teresa Ramirez‐Montagut, Mary Jo Turk, Jedd D. Wolchok, Jose Alejandro Guevara-Patino, Alan N. Houghton · 2003 · Oncogene
Targeting Intracellular Oncoproteins with Antibody Therapy or Vaccination
Ke Guo, Jie Li, Jing Ping Tang, Cheng Peow Bobby Tan, Cheng William Hong, Abdul Qader Al-Aidaroos, Leyon Varghese, Caixia Huang, Qi Zeng · 2011 · Science Translational Medicine
Combination Strategies to Enhance Antitumor ADCC
Holbrook E K Kohrt, Roch Houot, Aurélien Marabelle, Hearn Jay Cho, Keren Osman, Matthew Jordan Goldstein, Ronald Levy, Joshua Brody · 2012 · Immunotherapy
Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Ronald P. Taylor, Margaret A. Lindorfer · 2016 · Seminars in Immunology
Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving
Paul V. Beum, Margaret A. Lindorfer, Ronald P. Taylor · 2008 · The Journal of Immunology
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges
Mohammed Asif Chaudry, Kevin M. Sales, Peter Ruf, Horst Lindhofer, Marc C. Winslet · 2007 · British Journal of Cancer
Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
Josef Singer, Marlene Weichselbaumer, Thomas Stockner, Diana Mechtcheriakova, Yury Sobanov, Erika Bajna, Friedrich Wrba, Reinhard Horvat, Johann G. Thalhammer, Michael Willmann et al. · 2012 · Molecular Immunology
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs
Birgit Spänkuch, Elisabeth Kurunci‐Csacsko, M. Kaufmann, Klaus Strebhardt · 2007 · Oncogene
Complement and cellular cytotoxicity in antibody therapy of cancer
Siao‐Yi Wang, George J. Weiner · 2008 · Expert Opinion on Biological Therapy
Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
Linda C. Sandin, Anna Orlova, Erika Gustafsson, Peter Ellmark, Толмачев Владимир Максимилианович, Thomas H. Tötterman, Sara M. Mangsbo · 2013 · Cancer Immunology Research
The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
Jäger, Michael, Schoberth, Alexandra, Ruf, Peter, Hess, Jürgen, Lindhofer, Horst · 2009 · Cancer Research
Graft‐versus‐leukaemia effect after non‐myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP‐70 in refractory chronic lymphocytic leukaemia
Issa F. Khouri, Rima M. Saliba, Joan H. Admirand, Susan Mary O'Brien, Ming-S. Lee, Martin J. Korbling, Barry I. Samuels, Sergio Giralt, De Marcos Lima, Michael J. Keating et al. · 2007 · British Journal of Haematology
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
Gábor Tóth, Árpád Szöőr, László Simon, Yosef Yarden, János Szöllõsi, György Vereb · 2016 · mAbs
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity
Ruoxin Du, Xiangmei Zhang, Xiyan Lu, Xiangmin Ma, Xinyan Guo, Chao Shi, Xiaofei Ren, Xindi Ma, Yutong He, Yuan Gao et al. · 2023 · Drug Resistance Updates
Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice
Seungwon Kim, Christopher N. Prichard, Maher N. Younes, Yasemin Dakak Yazici, Samar A. Jasser, Benjamin Nebiyou Bekele, Jeffrey N. Myers · 2006 · Clinical Cancer Research
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
Andrew M. K. Law, Elgene Lim, Christopher John Ormandy, David Gallego‐Ortega · 2017 · Endocrine Related Cancer
Perspectives of HER2-targeting in gastric and esophageal cancer
James Nathan Gerson, Sam Skariah, Crystal Shereen Denlinger, Igor A. Astsaturov · 2017 · Expert Opinion on Investigational Drugs
Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study
Ningyan Zhang, Liming Liu, Calin Dan Dumitru, Nga Rewa Houston-Cummings, Michael C. Cukan, Youwei Jiang, Yuan Li, Fang Li, Teresa Mitchell, Muralidhar R. Mallem et al. · 2011 · mAbs
Fcγ receptors and immunomodulatory antibodies in cancer
Felipe Gálvez‐Cancino, Alexander P. Simpson, Cristóbal Costoya, Ignacio Garcia Matos, Danwen Qian, Karl S. Peggs, Kevin Litchfield, Sergio A. Quezada · 2023 · Nature reviews. Cancer
An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma
Stephen D. Gillies, Yan Lan, Steven Williams, Frank Carr, Stephen J. Forman, Andrew Antony Raubitschek, Kin-Ming Lo · 2005 · Blood
Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst
Christoph M. Rader, Subhash C. Sinha, Mikhail Popkov, Richard Alan Lerner, Carlos F. Barbas · 2003 · Proceedings of the National Academy of Sciences
Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity against Esophageal Squamous Cell Carcinoma
Kousaku Mimura, Koji Kono, Mitsuhiko Hanawa, Mirei Kanzaki, Atsuhito Nakao, Akishi Ooi, Hideki Fujii · 2005 · Clinical Cancer Research
There Is (Scientific) Strength in Numbers: A Comprehensive Quantitation of Fc Gamma Receptor Numbers on Human and Murine Peripheral Blood Leukocytes
Christina Kerntke, Falk Nimmerjahn, Markus Biburger · 2020 · Frontiers in Immunology
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
Claudia Stolz, Georg Heß, Patricia S. Hähnel, Florian Grabellus, Sandra Hoffarth, Kurt Werner Schmid, Martin Schüler · 2008 · Blood
CD20-Targeted Therapy: The Next Generation of Antibodies
Tom van Meerten, Anton Hagenbeek · 2010 · Seminars in Hematology
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Roberto Bianco, Teresa Troiani, Giampaolo Tortora, Fortunato Ciardiello · 2005 · Endocrine Related Cancer
Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine
Kenjiro Kimura, Tetsuji Sawada, Midori Komatsu, Masafumi Inoue, Kazuya Muguruma, Tamahiro Nishihara, Yoshito Yamashita, Nobuya Yamada, Masaichi Ohira, Kosei Hirakawa · 2006 · Clinical Cancer Research
Early Role of CD4+ Th1 Cells and Antibodies in HER-2 Adenovirus Vaccine Protection against Autochthonous Mammary Carcinomas
Jong Myun Park, Masaki Terabe, Yoshio Sakai, Jeeva Munasinghe, Guido Forni, John Charles Morris, Jay A. Berzofsky · 2005 · The Journal of Immunology
Fc γ receptors
Joël F.G. Cohen-Solal · 2004 · Immunology Letters
Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, Siqi, Lai, Seigmund W. T., Brown, Christine E., Feng, Mingye · 2021 · Frontiers in Immunology
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Kelly M. Quesnelle, Jennifer Rubin Grandis · 2011 · Clinical Cancer Research
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Alexey A. Larionov · 2018 · Frontiers in Oncology
FcγR: The key to optimize therapeutic antibodies?
Sophie Sibéril, Charles‐Antoine Dutertre, Wolf H. Fridman, Jean‐Luc Teillaud · 2007 · Critical Reviews in Oncology/Hematology
Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
Weiguo Hu, Xiaowen Ge, Tao You, Ting Xu, Jinyan Zhang, Gongxiong Wu, Zhihai Peng, Michael Chorev, Bertal Huseyin Aktas, José A. Halperin et al. · 2011 · Cancer Research
TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
Hailing Lu, Yi Yang, Ekram A. Gad, Carol Inatsuka, Cynthia A. Wenner, Mary Lenora Disis, Leanna J. Standish · 2011 · Clinical Cancer Research
Estimation of dose requirements for sustainedin vivoactivity of a therapeutic human anti‐CD20 antibody
Wim K. Bleeker, Martin E. Munk, Wendy J.M. Mackus, Jeroen H. N. van den Brakel, Marielle Pluyter, Martin J. Glennie, Jan G. J. van de Winkel, Paul W.H.I. Parren · 2007 · British Journal of Haematology
Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors
Damiano, Vincenzo, Caputo, Rosa, Bianco, Roberto, D'Armiento, Francesco P., Leonardi, Antonio, De Placido, Sabino, Bianco, A. Raffaele, Agrawal, Sudhir, Ciardiello, Fortunato, Tortora, Giampaolo · 2006 · Clinical Cancer Research
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Yong, Hannan, Raquibul, Fu, Yang-Xin · 2021 · Clinical Cancer Research
Potential Role of NK Cells in the Induction of Immune Responses: Implications for NK Cell–Based Immunotherapy for Cancers and Viral Infections
Hiroshi Terunuma, Xuewen Deng, Md. Zahidunnabi Dewan, Shigeyoshi Fujimoto, Naoki Yamamoto · 2008 · International Reviews of Immunology
In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas
Christel Larbouret, Bruno Robert, Isabelle Navarro‐Teulon, Simon Thézenas, Maha Zohra Ladjemi, Sébastien Morisseau, Emmanuelle Campigna, Frédéric Bibeau, Jean‐Pierre Mach, André Pèlegrin et al. · 2007 · Clinical Cancer Research
Neutrophils in the Antitumoral Immune Response
Emma Di Carlo, G Forni, Piero Musiani · 2003 · KARGER eBooks
Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing
Michael Dechant, Gestur Vidarsson, Bernhard Stockmeyer, Roland Repp, Martin J. Glennie, Martin Gramatzki, Jan G. J. van de Winkel, Thomas Valerius · 2002 · Blood
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma
Andre Cassell, Jennifer Rubin Grandis · 2010 · Expert Opinion on Investigational Drugs
Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids
Jin He, Troy A. Luster, Philip E. Thorpe · 2007 · Clinical Cancer Research